summari ew plan present result clasp
ce mark studi pascal transcathet mitral valv repair
tmvr devic upcom german cardiolog meet dgk
april abstract post on-line
chanc speak clinician data key takeaway
data efficaci pascal appear least
good abt mitraclip although three case
sever bleed pascal consult see reason
bleed would wors pascal compar mitraclip
technolog differ pascal mitraclip
help pascal captur least tmvr market time ew
plan present result clasp europcr may
pascal approv europ feb current model
total global ew transcathet mitral valv sale major
pascal increas rais
ew price target base
adj ep estim
clasp data look promis initi patient
clasp trial enrol site world-wide june
sept mean age year male
patient moder sever mitral regurgit mr
baselin almost patient function mr
slightli nyha class iii/iv sever heart failur
discharg patient mr mr
mild mr day mr reduct similar-to-slightli
better rate discharg day percentag
patient nyha class i/ii mild heart failur versu
less half baselin improv qualiti
life score regard sever advers event three
case sever bleed clinician
spoke concern explain us
device-rel reason bleed would
higher pascal mitraclip mani center clasp
trial experi pascal may
factor figur present side-by-sid comparison clasp
data mitraclip access eu data post-approv
studi europ note signific
differ patient popul clasp access eu
studi howev felt compar data
continu follow page
compani data secur llc estim reuter
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
continu previou page
pascal pascal spacer devic deliv via transeptal/transfemor approach
implant attach mitral valv leaflet reduc mitral regurgit mr pascal replic
surgic alfieri edge-to-edg procedur key featur pascal abil independ clasp
leaflet current possibl abt mitraclip although believ featur
develop avail abil independ grab leaflet
potenti make procedur faster easier also allow valv treat
larg flail one leaflet far apart pascal may also efficaci advantag
mitraclip grab leaflet make bigger bridg leaflet weve
also heard pascal deliveri system smaller easier move atrium one potenti
downsid pascal may caus gradient mitral stenosi mitraclip
bulkier like mitraclip pascal may also abl treat tricuspid regurgit
figur side-by-sid comparison pascal clasp data mitraclip access eu data
devicepascalmitraclipstudyclaspaccess class follow-upmr class chang baselin chang chang german cardiolog societi europcr secur llcnote mae major advers event nyha new york heart associ minut walk distanc kccq kansa citi cardiomyopathi questionnair edward lifesci corpor
price target
price target assum ep estim risk includ greater
share loss model delay mitral program neg clinic data
believ upcom data pipelin product help ew address new competit
transcathet mitral valv opportun signific catalyst
irvin california -base edward lifesci ew develop manufactur market product
design heart valv diseas cardiac surgeri critic care edward revenu reach
billion come transcathet heart valv therapi thv busi ew
player transcathet heart valv therapi market
